Brigimadlin

Generic Name
Brigimadlin
Brand Names
-
Drug Type
Small Molecule
Chemical Formula
C31H25Cl2FN4O3
CAS Number
2095116-40-6
Unique Ingredient Identifier
9A934ZAN94
Associated Conditions
-
Associated Therapies
-

A Study to Test Long-term Treatment With Brigimadlin in People With Solid Tumours Who Took Part in a Previous Study With This Medicine

Phase 2
Not yet recruiting
Conditions
Interventions
First Posted Date
2024-10-01
Last Posted Date
2024-12-20
Lead Sponsor
Boehringer Ingelheim
Target Recruit Count
50
Registration Number
NCT06619509
Locations
🇪🇸

Fundación Jiménez Díaz, Madrid, Spain

🇪🇸

Hospital Clínico San Carlos, Madrid, Spain

🇪🇸

Hospital Universitario 12 de Octubre, Madrid, Spain

and more 25 locations

Brightline-4: A Study to Test How Well Brigimadlin is Tolerated by People With a Type of Cancer Called Dedifferentiated Liposarcoma

Phase 3
Active, not recruiting
Conditions
Interventions
First Posted Date
2023-09-28
Last Posted Date
2024-11-13
Lead Sponsor
Boehringer Ingelheim
Target Recruit Count
240
Registration Number
NCT06058793
Locations
🇯🇵

National Cancer Center Hospital, Tokyo, Chuo-ku, Japan

🇺🇸

Precision NextGen Oncology, Beverly Hills, California, United States

🇺🇸

Sarcoma Oncology Center, Santa Monica, California, United States

and more 58 locations

Brightline-2: A Study to Test Whether Brigimadlin (BI 907828) Helps People With Cancer in the Biliary Tract, Pancreas, Lung or Bladder

First Posted Date
2022-08-23
Last Posted Date
2024-12-20
Lead Sponsor
Boehringer Ingelheim
Target Recruit Count
99
Registration Number
NCT05512377
Locations
🇩🇪

Klinikum der Universität München AÖR, München, Germany

🇩🇪

Universitätsklinikum Ulm, Ulm, Germany

🇺🇸

Southern Cancer Center, Mobile, Alabama, United States

and more 40 locations
© Copyright 2024. All Rights Reserved by MedPath